Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

ATAI Life Sciences BV

ATAI
Current price
1.21 USD +0.04 USD (+3.42%)
Last closed 1.15 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 185 931 200 USD
Yield for 12 month -62.19 %
Week
Month
Year
ATAI
21.11.2021 - 28.11.2021

ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London. Address: Krausenstrasse 9-10, Berlin, Germany, 10117

Analytics

WallStreet Target Price

12.32 USD

P/E ratio

Dividend Yield

Current Year

+233 000 USD

Last Year

+20 376 000 USD

Current Quarter

+87 000 USD

Last Quarter

+172 000 USD

Current Year

+233 000 USD

Last Year

+20 376 000 USD

Current Quarter

+87 000 USD

Last Quarter

+172 000 USD

Key Figures ATAI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -125 998 000 USD
Operating Margin TTM -30843.68 %
PE Ratio
Return On Assets TTM -24.25 %
PEG Ratio
Return On Equity TTM -25.29 %
Wall Street Target Price 12.32 USD
Revenue TTM 334 000 USD
Book Value 1.6 USD
Revenue Per Share TTM 0.002 USD
Dividend Share
Quarterly Revenue Growth YOY 262.5 %
Dividend Yield
Gross Profit TTM 233 000 USD
Earnings Share -0.43 USD
Diluted Eps TTM -0.43 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY -96.8 %
Profit Margin

Dividend Analytics ATAI

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ATAI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ATAI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 529.7822
Price Sales TTM 556.6802
Enterprise Value EBITDA 0.0703
Price Book MRQ 0.7045

Financials ATAI

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators ATAI

For 52 weeks

1.03 USD 3.65 USD
50 Day MA 1.23 USD
Shares Short Prior Month 5 628 406
200 Day MA 1.61 USD
Short Ratio 10.51
Shares Short 5 090 401
Short Percent 4.01 %